Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kalaris Therapeutics, Inc. (KLRS)

Kalaris Therapeutics names Liisa Bayko CFO; CAO Brett Hagen to resign July 27

Neutral Impact 4 of 5 leadership Written later

Kalaris Therapeutics appointed Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026, and she will also serve as principal financial officer. The company also disclosed that Chief Accounting Officer Brett Hagen is resigning effective July 27, 2026, and Corporate Controller Amy Vandekop will serve as interim principal accounting officer.

Key points

  • Liisa Bayko's annualized base salary is $475,000, with an annual target bonus of up to 40.0% of base salary.
  • Bayko received an incentive stock option to purchase up to 220,000 shares of common stock, vesting 25% on the first anniversary of the effective date and then in 36 monthly installments.
  • Bayko previously was Managing Director, Biotech Equity Research at Evercore ISI from August 2020 to December 2025.
  • Brett Hagen notified the company on July 14, 2026 of his resignation as SVP, Finance and Chief Accounting Officer, effective July 27, 2026.

The filing

CompanyKalaris Therapeutics, Inc. (KLRS)
Form8-K, current report
Filed with the SECJul 20, 2026, 8:07 AM ET
Accession number0001193125-26-308382

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.